Evotec SE lowered its full-year 2026 guidance after reporting preliminary unaudited financial results for the first half of the year, citing weaker-than-expected performance. The company now anticipates full-year Group revenues of approximately €570 to 610 million, down from the previous guidance of €700 to 780 million. Adjusted Group EBITDA is now projected to be between -€70 and -€105 million, a sharp decline from the previously expected range of €0 to 40 million.

Based on preliminary figures, Evotec recorded Group revenues of approximately €300.1 million for the first half of 2026. Adjusted Group EBITDA for the same period stood at approximately -€42.7 million. As of June 30, 2026, the company reported liquidity of approximately €465.6 million.

The revised outlook reflects current operational performance and market conditions. Full financial results for the second quarter and first half of 2026 are scheduled to be published on August 13, 2026.

Financial Outlook Comparison

The following table compares the updated full-year 2026 guidance with the company's previous projections:

The company continues to maintain a strong liquidity position, which it expects will support operations through the remainder of the fiscal year.

Evotec SE announced the launch of J.TRAIN, a turnkey solution enabling biopharmaceutical companies to deploy its proprietary continuous manufacturing technology directly within their own facilities. The new offering, unveiled on June 30, 2026, combines prefabricated modular cleanrooms and industry-standard equipment with cGMP-compliant process automation to accelerate capacity expansion. J.TRAIN is designed to offer significantly faster and more cost-effective deployment compared to traditional manufacturing expansion methods.

The solution represents a strategic shift for Just – Evotec Biologics, a wholly-owned subsidiary of Evotec SE, toward a technology-focused and capital-lighter business model. Linda Zuckerman, PhD, EVP Global Head of Just – Evotec Biologics, highlighted that the model was validated by a December 2025 transaction with Sandoz. This transaction included the provision of a manufacturing facility alongside a license to the proprietary manufacturing technology, demonstrating its feasibility and scalability.

J.TRAIN aims to deliver a step change in productivity and efficiency compared to conventional fed-batch approaches. The system can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space. This configuration achieves productivity levels more than ten times traditional methods, which is expected to translate into substantially lower operating costs per unit mass.

The integrated design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments. Production scale can be flexibly adjusted through the duration of manufacturing runs rather than relying on the size of the facility. Proprietary automation scripts for continuous process control, along with digital validation and documentation protocols, are included to streamline implementation and ensure regulatory readiness.

With deployment timelines of approximately 18 months, J.TRAIN offers a faster pathway to capacity expansion than traditional biologics manufacturing facilities. The solution was initially unveiled in April 2026 at the INTERPHEX conference in New York City.

Key Features of J.TRAIN